# Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™

> **NCT00802867** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 989 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Polio
- Haemophilus Infection

## Interventions

- **BIOLOGICAL:** Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)

## Key facts

- **NCT ID:** NCT00802867
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2005-06
- **Final completion:** 2005-09
- **Target enrollment:** 989 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802867, "Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00802867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*